These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 22252140)

  • 41. Cancer Drug Development: New Targets for Cancer Treatment.
    Curt GA
    Oncologist; 1996; 1(3):II-III. PubMed ID: 10387987
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Microbioreactors for high-throughput cytotoxicity assays.
    Yang ST; Zhang X; Wen Y
    Curr Opin Drug Discov Devel; 2008 Jan; 11(1):111-27. PubMed ID: 18175274
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Biofabrication of a three-dimensional liver micro-organ as an in vitro drug metabolism model.
    Chang R; Emami K; Wu H; Sun W
    Biofabrication; 2010 Dec; 2(4):045004. PubMed ID: 21079286
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The application of 3D cell models to support drug safety assessment: opportunities & challenges.
    Roth A; Singer T
    Adv Drug Deliv Rev; 2014 Apr; 69-70():179-89. PubMed ID: 24378580
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Drug and bioactive molecule screening based on a bioelectrical impedance cell culture platform.
    Ramasamy S; Bennet D; Kim S
    Int J Nanomedicine; 2014; 9():5789-809. PubMed ID: 25525360
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Metabolic enzyme microarray coupled with miniaturized cell-culture array technology for high-throughput toxicity screening.
    Lee MY; Dordick JS; Clark DS
    Methods Mol Biol; 2010; 632():221-37. PubMed ID: 20217581
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Drug discovery through stem cell-based organoid models.
    Ranga A; Gjorevski N; Lutolf MP
    Adv Drug Deliv Rev; 2014 Apr; 69-70():19-28. PubMed ID: 24582599
    [TBL] [Abstract][Full Text] [Related]  

  • 48. On-chip investigation of cell-drug interactions.
    Zheng XT; Yu L; Li P; Dong H; Wang Y; Liu Y; Li CM
    Adv Drug Deliv Rev; 2013 Nov; 65(11-12):1556-74. PubMed ID: 23428898
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Three-dimensional cell culture: the missing link in drug discovery.
    Breslin S; O'Driscoll L
    Drug Discov Today; 2013 Mar; 18(5-6):240-9. PubMed ID: 23073387
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Assessing nanoparticle toxicity in cell-based assays: influence of cell culture parameters and optimized models for bridging the in vitro-in vivo gap.
    Joris F; Manshian BB; Peynshaert K; De Smedt SC; Braeckmans K; Soenen SJ
    Chem Soc Rev; 2013 Nov; 42(21):8339-59. PubMed ID: 23877583
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The value of alternative testing for neurotoxicity in the context of regulatory needs.
    Coecke S; Eskes C; Gartlon J; Kinsner A; Price A; van Vliet E; Prieto P; Boveri M; Bremer S; Adler S; Pellizzer C; Wendel A; Hartung T
    Environ Toxicol Pharmacol; 2006 Feb; 21(2):153-67. PubMed ID: 21783653
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Consideration of the cellular microenvironment: physiologically relevant co-culture systems in drug discovery.
    L Berg E; Hsu YC; Lee JA
    Adv Drug Deliv Rev; 2014 Apr; 69-70():190-204. PubMed ID: 24524933
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cell cultures in drug discovery and development: The need of reliable in vitro-in vivo extrapolation for pharmacodynamics and pharmacokinetics assessment.
    Jaroch K; Jaroch A; Bojko B
    J Pharm Biomed Anal; 2018 Jan; 147():297-312. PubMed ID: 28811111
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Functional drug candidate profiling using complex human organotypic cell culture models: a promising way to reduce clinical drug failure.
    Schmolz M
    Expert Opin Drug Discov; 2007 Jul; 2(7):935-47. PubMed ID: 23484814
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Probe molecule (PrM) approach in adverse outcome pathway (AOP) based high-throughput screening (HTS): in vivo discovery for developing in vitro target methods.
    Angrish MM; Madden MC; Pleil JD
    Chem Res Toxicol; 2015 Apr; 28(4):551-9. PubMed ID: 25692543
    [TBL] [Abstract][Full Text] [Related]  

  • 56. In vitro models to study hepatotoxicity.
    Groneberg DA; Grosse-Siestrup C; Fischer A
    Toxicol Pathol; 2002; 30(3):394-9. PubMed ID: 12051557
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Integrating High-Dimensional Transcriptomics and Image Analysis Tools into Early Safety Screening: Proof of Concept for a New Early Drug Development Strategy.
    Verbist BM; Verheyen GR; Vervoort L; Crabbe M; Beerens D; Bosmans C; Jaensch S; Osselaer S; Talloen W; Van den Wyngaert I; Van Hecke G; Wuyts D; ; Van Goethem F; Göhlmann HW
    Chem Res Toxicol; 2015 Oct; 28(10):1914-25. PubMed ID: 26313431
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Stretching mechanotransduction from the lung to the lab: approaches and physiological relevance in drug discovery.
    Schmitt S; Hendricks P; Weir J; Somasundaram R; Sittampalam GS; Nirmalanandhan VS
    Assay Drug Dev Technol; 2012 Apr; 10(2):137-47. PubMed ID: 22352900
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Three-dimensional tissue models for drug discovery and toxicology.
    Pampaloni F; Stelzer EH; Masotti A
    Recent Pat Biotechnol; 2009; 3(2):103-17. PubMed ID: 19519566
    [TBL] [Abstract][Full Text] [Related]  

  • 60. OrganDots--an organotypic 3D tissue culture platform for drug development.
    Sundstrom L; Biggs T; Laskowski A; Stoppini L
    Expert Opin Drug Discov; 2012 Jun; 7(6):525-34. PubMed ID: 22607235
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.